<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423798</url>
  </required_header>
  <id_info>
    <org_study_id>CEP 296</org_study_id>
    <nct_id>NCT02423798</nct_id>
  </id_info>
  <brief_title>New Generation Enlite Accuracy Study</brief_title>
  <official_title>Accuracy and Performance Evaluation of the Medtronic New Generation Enlite Glucose Sensor in Conjunction With the Medtronic 640G System Components - in Clinic and at Home</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Profil Institut f√ºr Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will investigate the accuracy and performance of a new sensor for continuous
      glucose monitoring (CGM), the (new generation) Enlite, CE-marked in 2013, in conjunction with
      the new Medtronic 640G system components.

      To evaluate the accuracy and performance of the new generation Enlite sensor. This is a
      postmarket, interventional, open-label, non-randomized, single center clinical research
      trial.

      The trial will adopt a prospective single-sample design using the Yellow Spring Instruments
      (YSI) plasma glucose reference sampling procedure in the clinic and self-monitoring of blood
      glucose (SMBG) plasma glucose reference sampling procedure at home.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will investigate the accuracy and performance (i.e. the life-time) of a new sensor
      for CGM, the (new generation) Enlite glucose sensor, CE-marked in 2013, in conjunction with
      the new Medtronic 640G system components. Accuracy and life-time of the sensor are important
      parameters contributing to the safety of patients and patient acceptance of this still fairly
      new technology.

      The current trial investigates the accuracy of the new sensor in conjunction with the new
      640G system components both in the clinic and at home. This enables us to assess the sensor
      accuracy in a well-controlled environment using a highly accurate laboratory glucose analyzer
      as reference as well as sensor accuracy during real-life conditions using a blood glucose
      meter as reference analyzer.

      The data gathered in this trial will help to understand the effect of technological
      advancements made and can guide future development of glucose sensor for continuous glucose
      monitoring.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensor Accuracy</measure>
    <time_frame>4 months</time_frame>
    <description>Sensor values were compared to YSI plasma glucose values, which is considered as the gold standard, during the frequent sample testing day (day 3). MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Consensus Error Grid Analysis of Paired Sensor and Reference Plasma Glucose Values</measure>
    <time_frame>4 months</time_frame>
    <description>All analysis performed using the Consensus Error Grid (or Parkes error grid) comparing the paired sensor and YSI reference glucose values.
Zone A is defined in the Parkes error grid as the zone of &quot;clinical accurate measurements with no effect on clinical action.&quot; Zone B as &quot;altered clinical action with little or no effect on clinical outcome.&quot;. Ideal situation is 100% in Zone A + B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensor Survival</measure>
    <time_frame>4 months</time_frame>
    <description>sensor survival in hours</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Open-label, single-sample design</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The trial has an open label design with a glucose sensor intervention. Only 1 sensor system is used in the trial (no comparator).
As all subjects will receive identical devices and undergo the same experimental procedures, no randomization will be performed. Furthermore, neither subjects nor clinical staff will be blinded to the sensor readings, as knowing the sensor glucose readings will not affect the accuracy endpoint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glucose sensor (Enlite)</intervention_name>
    <description>This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).</description>
    <arm_group_label>Open-label, single-sample design</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has signed the informed consent form prior to screening

          -  Age 18-74 years (both inclusive)

          -  Subject has been diagnosed with T1DM

          -  Subject is current insulin pump user for at least 3 months

          -  HbA1c 9.5%

          -  With the exception of T1DM, the subject is considered generally healthy upon
             completion of medical history, physical examination, vital signs, ECG and biochemical
             investigations as judged by the Investigator

        Exclusion Criteria:

          -  Female of childbearing potential who is pregnant, breast-feeding or intend to become
             pregnant or are not using adequate contraceptive methods (adequate contraceptive
             measures include sterilization, hormonal intrauterine devices, oral contraceptives,
             sexual abstinence, vasectomized partner)

          -  Subject has any condition that, in the opinion of the Investigator or qualified
             Investigational Centre staff, may preclude him/her from participating in the study and
             completing study related procedures.

          -  Subject has impaired vision or hearing problems that could compromise the handling of
             the device as determined by Investigator or qualified Investigational Centre staff

          -  Subject is unable to tolerate tape adhesive in the area of sensor placement

          -  Subject has any unresolved adverse skin condition in the area of sensor placement
             (e.g. psoriasis, rash, Staphylococcus infection)

          -  Subject has travel plans which would make it difficult for the subject to attend
             on-site study visits as scheduled

          -  Subject is actively participating in an investigational study (drug or device) wherein
             he/she has received treatment from an investigational study drug or investigational
             study device in the last 30 days

          -  Subject known to be positive for Hepatitis B surface antigen (HBsAg) or Hepatitis C
             antibodies (or diagnosed with active hepatitis according to local practice).

          -  Positive result to the screening test for HIV-1 antibodies, HIV-2 antibodies or HIV-1
             antigen according to locally used diagnostic testing

          -  Significant history of alcoholism or drug/chemical abuse as per investigator's
             judgment, current regular alcohol consumption of more than 1 unit per day for women
             and more than 2 units per day for men [1 unit of alcohol equals 1 beer (330 mL), 1
             glass of wine (120 mL), or 1 glass of spirits (40 mL)], or a positive result in the
             urine drug/alcohol screen at the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <results_first_submitted>August 28, 2017</results_first_submitted>
  <results_first_submitted_qc>August 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2017</results_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Glucose sensor</keyword>
  <keyword>Sensor accuracy and performance</keyword>
  <keyword>CGM</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All Subjects</recruitment_details>
      <pre_assignment_details>All Subjects</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>All subjects will receive identical devices and undergo the same experimental procedures.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All Subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensor Accuracy</title>
        <description>Sensor values were compared to YSI plasma glucose values, which is considered as the gold standard, during the frequent sample testing day (day 3). MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100).</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>All Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Sensor Accuracy</title>
          <description>Sensor values were compared to YSI plasma glucose values, which is considered as the gold standard, during the frequent sample testing day (day 3). MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100).</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.13" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean</param_type>
            <param_value>9.13</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Consensus Error Grid Analysis of Paired Sensor and Reference Plasma Glucose Values</title>
        <description>All analysis performed using the Consensus Error Grid (or Parkes error grid) comparing the paired sensor and YSI reference glucose values.
Zone A is defined in the Parkes error grid as the zone of ‚Äúclinical accurate measurements with no effect on clinical action.‚Äù Zone B as ‚Äúaltered clinical action with little or no effect on clinical outcome.‚Äù. Ideal situation is 100% in Zone A + B.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>All Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Consensus Error Grid Analysis of Paired Sensor and Reference Plasma Glucose Values</title>
          <description>All analysis performed using the Consensus Error Grid (or Parkes error grid) comparing the paired sensor and YSI reference glucose values.
Zone A is defined in the Parkes error grid as the zone of ‚Äúclinical accurate measurements with no effect on clinical action.‚Äù Zone B as ‚Äúaltered clinical action with little or no effect on clinical outcome.‚Äù. Ideal situation is 100% in Zone A + B.</description>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sensor Survival</title>
        <description>sensor survival in hours</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
          </group>
        </group_list>
        <measure>
          <title>Sensor Survival</title>
          <description>sensor survival in hours</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.8" lower_limit="115.7" upper_limit="145.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>itching at sensor insertion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>hematoma at insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>erythema at insertion site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>mild erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Odile O'Sullivan, Clinical Trial Manager</name_or_title>
      <organization>Medtronic Minimed</organization>
      <phone>8184763319</phone>
      <email>odile.osullivan@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

